Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968015 | 0.80 | CTSC (0.38) | CTSCCA14CA12CA7CA9 | |
| SCHEMBL19015917 | 0.80 | CTSC (0.38) | CTSCCA14CA12CA7CA9 | |
| SCHEMBL21939197 | 0.72 | TSHR (0.34) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL7593049 | 0.71 | — | — | |
| SCHEMBL7888162 | 0.71 | CTSK (0.43) | CA14CA12CA7CASP3 | |
| SCHEMBL7901755 | 0.70 | ALDH1A1 (0.42) | TSHRMAPTALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL7908837 | 0.70 | ALDH1A1 (0.42) | TSHRMAPTALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL13453162 | 0.70 | TAS1R3 (0.40) | TSHRALDH1A1 | |
| SCHEMBL161790 | 0.70 | — | — | |
| SCHEMBL1143953 | 0.68 | TSHR (0.39) | CA14CA12CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | GENESIS TECH LTD (BB) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114092-A1 | SELECTIVE CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP3, CASP5 | CTSC 158/4885CA14 3686/4885CA12 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.